Legend Biotech Reports Strong Q2 2025 Results and CARVYKTI® Success

An update from Legend Biotech ( (LEGN) ) is now available.

Legend Biotech reported its second quarter 2025 financial results, highlighting significant achievements in its CAR-T cell therapy programs. The company revealed that CARVYKTI® net trade sales reached approximately $439 million, with positive long-term outcomes demonstrated in the CARTITUDE-1 study, where one-third of patients remained progression-free for over five years. The company also presented new data at the ASCO meeting and announced regulatory updates, including the FDA’s removal of certain monitoring requirements for CARVYKTI. Financially, Legend Biotech reported a cash position of $1.0 billion, which is expected to support operations into 2026, with a goal of achieving profitability by then. The company’s collaboration revenue increased significantly due to sales of CARVYKTI®, and it continues to expand its manufacturing capacity to support growing demand.

The most recent analyst rating on (LEGN) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.

Spark’s Take on LEGN Stock

According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.

Legend Biotech’s overall score is driven by strong revenue growth and positive earnings call sentiment, but is offset by ongoing unprofitability and cash flow challenges. Technical indicators provide a mixed view, and valuation remains a concern due to the negative P/E ratio.

To see Spark’s full report on LEGN stock, click here.

More about Legend Biotech

Legend Biotech Corporation is a leading cell therapy company focused on developing innovative treatments for cancer. The company is at the forefront of the CAR-T cell therapy revolution with its product CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, developed in collaboration with Johnson & Johnson. Legend Biotech is headquartered in Somerset, New Jersey, and is expanding its leadership in cell therapy to maximize patient access and therapeutic potential.

Average Trading Volume: 1,721,262

Technical Sentiment Signal: Hold

Current Market Cap: $6.81B

For a thorough assessment of LEGN stock, go to TipRanks’ Stock Analysis page.